XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.4

Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table summarizes the changes in the carrying amount of Goodwill:

						December 31,
(in millions)						2022						2021
Beginning balance						$	8,332					$	8,108
Goodwill resulting from acquisitions						—						226
Measurement period adjustments						(18)						(2)
Ending balance						$	8,314					$	8,332

Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

						December 31, 2022																								December 31, 2021
(in millions)						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir						$	10,720					$	(6,350)					$	—					$	4,370					$	10,720					$	(5,651)					$	—					$	5,069
Intangible asset – axicabtagene ciloleucel						7,110						(1,908)						—						5,202						7,110						(1,501)						—						5,609
Intangible asset – Trodelvy						5,630						(973)						—						4,657						5,630						(507)						—						5,123
Intangible asset – Hepcludex						845						(158)						—						687						845						(72)						—						773
Other						1,489						(733)						1						758						1,610						(650)						1						961
Total finite-lived assets						25,794						(10,121)						1						15,674						25,915						(8,381)						1						17,535
Indefinite-lived assets – IPR&D(1)						13,220						—						—						13,220						15,920						—						—						15,920
Total intangible assets						$	39,014					$	(10,121)					$	1					$	28,894					$	41,835					$	(8,381)					$	1					$	33,455

_______________________________

(1)    In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion will be reclassified to finite-lived assets in the first quarter of 2023.

Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

						December 31, 2022																								December 31, 2021
(in millions)						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir						$	10,720					$	(6,350)					$	—					$	4,370					$	10,720					$	(5,651)					$	—					$	5,069
Intangible asset – axicabtagene ciloleucel						7,110						(1,908)						—						5,202						7,110						(1,501)						—						5,609
Intangible asset – Trodelvy						5,630						(973)						—						4,657						5,630						(507)						—						5,123
Intangible asset – Hepcludex						845						(158)						—						687						845						(72)						—						773
Other						1,489						(733)						1						758						1,610						(650)						1						961
Total finite-lived assets						25,794						(10,121)						1						15,674						25,915						(8,381)						1						17,535
Indefinite-lived assets – IPR&D(1)						13,220						—						—						13,220						15,920						—						—						15,920
Total intangible assets						$	39,014					$	(10,121)					$	1					$	28,894					$	41,835					$	(8,381)					$	1					$	33,455

Estimated Future Amortization Expense of Finite-Lived Intangible Assets

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2022:

(in millions)						Amount
2023						$	1,777
2024						1,777
2025						1,771
2026						1,763
2027						1,763
Thereafter						6,824
Total						$	15,674

X

- References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Name:	us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b),(d)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration